insights_auto
Nega ABVX tushdi 2,78%?
Batafsil oʻrganishchevron_right
ABVX:EPA
Abivax SA
76,90 €
arrow_downward
-2,78%(-2,20) 1K
16-noy, 17:35:03 (GMT+1) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoABVX tikeri uchun statistika yaratilmoqda...
Ochish
79,00 €
Yuqori
80,05 €
Past
76,90 €
Bozor kapitali
6,63 mlrd
Oʻrtacha hajm
109,70 ming
Hajmi
89,36 ming
52 haftalik eng yuqori
139,00 €
52 haftalik eng past
60,45 €
Aksiya boʻyicha daromad
-5,20 €
Muomaladagi aksiyalar
87,55 mln
Xodimlar soni
98
Ochish
79,00 €
Yuqori
80,05 €
Past
76,90 €
Bozor kapitali
6,63 mlrd
Oʻrtacha hajm
109,70 ming
Hajmi
89,36 ming
52 haftalik eng yuqori
139,00 €
52 haftalik eng past
60,45 €
Aksiya boʻyicha daromad
-5,20 €
Muomaladagi aksiyalar
87,55 mln
Xodimlar soni
98
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Idéal Investisseur
·
3 soat oldin
Abivax shares slip back below €76.05, in the lower ranks of the SBF 120
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA haqida
CEOMarc de Garidel | Hartmut J. Ehrlich
Xodimlar soni98
Asos solingan4-dek, 2013
Bosh ofislar-
SektorHealth Care
Soha-
Veb-saytabivax.com